Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

被引：87
|
作者：
Hamilton, Chad A. [1 ]
Maxwell, G. Larry [1 ]
Chemofsky, Mildred R. [1 ]
Bernstein, Sarah A. [1 ]
Farley, John H. [1 ]
Rose, G. Scott [1 ]
机构：
[1] Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Washington, DC 20307 USA
来源：
GYNECOLOGIC ONCOLOGY | 2008年 / 111卷 / 03期
关键词：
Bevacizumab; Intraperitoneal; Ovarian cancer; Ascites; Palliation;
D O I：
10.1016/j.ygyno.2008.04.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background. Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case. We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion. Intraperitoneal bevacizumab may be a useful 1001 in the palliation of malignant ascites and is worthy of further study. Published by Elsevier Inc.
引用
收藏
页码：530 / 532
页数：3
相关论文
共 50 条
  • [21] Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites
    Naminatsu Takahara
    Hiroyuki Isayama
    Yousuke Nakai
    Hironori Ishigami
    Sohei Satoi
    Suguru Mizuno
    Hirofumi Kogure
    Saburo Matsubara
    Natsuyo Yamamoto
    Hironori Yamaguchi
    Minoru Tada
    Joji Kitayama
    Toshiaki Watanabe
    Kazuhiko Koike
    Investigational New Drugs, 2016, 34 : 636 - 642
  • [22] Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy
    Patriti, Alberto
    Cavazzoni, Emanuel
    Graziosi, Luigina
    Pisciaroli, Antonio
    Luzi, Debora
    Gulla, Nino
    Donini, Annibale
    SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, 2008, 18 (04): : 426 - 428
  • [23] Hyperthermic Intraperitoneal Perfusion Chemotherapy and Cytoreductive Surgery for Controlling Malignant Ascites From Ovarian Cancer
    Ba, Mingchen
    Long, Hui
    Zhang, Xiangliang
    Tang, Yunqiang
    Wu, Yinbing
    Wang, Shuai
    Yan, Zhaofei
    Zhang, Bohuo
    Cui, Shuzhong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (09) : 1571 - 1579
  • [24] Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
    Kondo, Tomohiro
    Kitayama, Hiromitsu
    Sugiyama, Junko
    Hirayama, Michiaki
    Suzuki, Yoshinori
    Oyamada, Yumiko
    Tsuji, Yasushi
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (06) : 740 - 744
  • [25] Use of 7.5 mg/kg of bevacizumab to palliate symptomatic malignant ascites in recurrent ovarian cancer
    Shimizu, Y.
    Nakanishi, T.
    Sasamoto, K.
    Kondo, S.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (03) : 404 - 407
  • [26] The role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer
    Nikolaou, M.
    Ziras, N.
    Athanasiadis, I.
    Ardavanis, A.
    Vaslamatzis, M.
    Kentepozidis, N.
    Makrantonakis, P.
    Christopoulou, A. N.
    Michalaki, V.
    Polizos, A.
    Emmanouilidis, C.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Bevacizumab administered intraperitoneally as palliative treatment of malignant refractory ascites.
    Mateescu, Cristian
    Becq, Aymeric
    Bouattour, Mohamed
    Dreyer, Chantal
    Falvre, Sandrine J.
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
    Numnum, T. Michael
    Rocconi, Rodney P.
    Whitworth, Jenny
    Barnes, Mack N.
    GYNECOLOGIC ONCOLOGY, 2006, 102 (03) : 425 - 428
  • [29] Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: An interim analysis
    Takahara, Naminatsu
    Isayama, Hiroyuki
    Nakai, Yousuke
    Sasaki, Takashi
    Ishigami, Hironori
    Yamaguchi, Hironori
    Kogure, Hirofumi
    Yamamoto, Natsuyo
    Hirano, Naoki Sasahira Kenji
    Tada, Minoru
    Kitayama, Joji
    Watanabe, Toshiaki
    Koike, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [30] Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis
    Takahara N.
    Isayama H.
    Nakai Y.
    Sasaki T.
    Ishigami H.
    Yamashita H.
    Yamaguchi H.
    Hamada T.
    Uchino R.
    Mizuno S.
    Miyabayashi K.
    Mohri D.
    Kawakubo K.
    Kogure H.
    Yamamoto N.
    Sasahira N.
    Hirano K.
    Ijichi H.
    Tateishi K.
    Tada M.
    Kitayama J.
    Watanabe T.
    Koike K.
    Journal of Gastrointestinal Cancer, 2014, 45 (3) : 307 - 311
12345